STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)
July to September
January to September
Significant events during January – September
Events after the reporting period
” In my role as liquidator, I continue to review opportunities for a strategic transaction supported by the management team of the company that have been given notice of termination quote.”
Lars-Henrik Andersson, Liquidator
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of locally administered first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s leading project, ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The company aslo deems that the product candidate potentially can be used for other indications, such as treatment of diabetic foot ulcers and cancer wounds. The company is listed on Nasdaq First North Growth Market.
Link to the report on our site
The full interim report is available at https://www.promorepharma.com/en/section/investors/financial-reports/
Attachments
Promore Pharma Q3 2023 ENG FINAL
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/810687/interim-report-january-september-2023
LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification…
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG,…
GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…
WESTLAKE, Texas, July 9, 2024 /PRNewswire/ -- AvodahMed is pleased to announce the appointment of…
ALLENTOWN, Pa., July 9, 2024 /PRNewswire/ -- HNL Lab Medicine is excited to announce the…
Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…